alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

This trial is testing a new type of immune cell therapy called CYAD-101 — made from donor T cells that are modified to attack colon and rectal cancer — combined with standard chemotherapy (FOLFOX or FOLFIRI), in patients with advanced colorectal cancer that has spread and is no longer responding to standard treatments. **You may be eligible if...** - You have been diagnosed with metastatic (spread) colorectal cancer that cannot be surgically removed - Your cancer has progressed after at least one prior chemotherapy regimen for metastatic disease - Your cancer can be measured on scans - You are well enough to carry out daily activities (ECOG 0 or 1) - Your bone marrow, liver, kidney, lung, and heart function are adequate **You may NOT be eligible if...** - Your cancer has spread to the brain or spinal cord - You have had a prior bone marrow transplant, CAR T-cell therapy, or other gene-modified T-cell therapy - You received certain other investigational drugs recently - You received certain growth factor medications within 7 days of planned treatment Talk to your doctor to see if this trial is right for you.